TEVA’s TEV-408 posts robust phase IIa celiac results
TEVA’s anti-IL-15 antibody TEV-408 showed statistically and clinically significant gut-architecture protection and reduced inflammation in a phase IIa celiac disease study, with a favorable safety profile and symptom-improvement trends.
TEV-408, an anti-IL-15 antibody, demonstrated statistically and clinically significant protection of gut architecture and reduced inflammation in a phase IIa celiac disease study, with a favorable safety profile and symptom improvement trends.
The results support rapid advancement to later-stage tr…